Ann E. Berman - 15 Mar 2022 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 15 Mar 2022
Net transaction value: +$38,400
SEC form: 4
Accepted by SEC: 15 Mar 2022, 17:53:34 UTC
Prior SEC filing: 02 Mar 2022
Next SEC filing: 11 May 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman

Key filing fact

Ann E. Berman filed Form 4 for Immuneering Corp (IMRX) on 15 Mar 2022.

Key facts

This page summarizes Ann E. Berman's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Mar 2022, 17:53.

Change

Previous filing in this sequence was filed on 02 Mar 2022.
Current net transaction value: +$38,400.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMRX transaction

Class A Common Stock

Purchase

Transaction value: $38,400
Shares: +6,000
Change %: +171%
Price: $6.40
Shares after: 9,500
Date: 15 Mar 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $6.35 to $6.45. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares acquired at each price.